«As we enter the new year, the latest developments in artificial intelligence hold the promise to transform almost every aspect of drug R&D. Our ability to access large datasets, rapid increases in computing power, and more precise algorithms are transforming end-to-end drug discovery. It will impact how we identify new targets and validate them, lead generation, patient identification, and how we design clinical trials and real-world data. We can anticipate vast improvements in clinical trial timelines and cost. All of these will work to improve patient outcomes with faster access to new breakthroughs.»

«But there are important barriers that could impede AI’s potential. The pharmaceutical industry needs to challenge existing attitudes and behavior, adapt to lessons learned, and improve insights that will enable us to use AI ethically and safely.»

Article written by PAUL HUDSON



Fast Company